Daily weight-loss pills cannot outcompete the extreme convenience of once-monthly injections.
The clinical progression toward ultra-long-acting monthly formulations is compressing the commercial potential and market valuations of daily oral obesity drugs.
The same conclusion keeps arriving from across the workspace's research — 2 topics independently instantiate this theme. Filter the evidence by where it came from:
Clinical progression toward monthly or bimonthly formulations highlights the market's focus on long-acting convenience over daily administration.
Strong clinical showing of monthly dosing validates the extreme commercial and convenience threat that ultra-long-acting formulations pose to daily alternatives.
Viking is proactively testing monthly subcutaneous injections as a weight-maintenance strategy to align with current medical and market preferences.
Oral pipeline candidates face severely reduced commercial opportunities when positioned against the lighter compliance burden of once-monthly options.
The rise of highly effective monthly injectables is depressing the valuations of biotech players developing daily oral obesity drugs because of the superior convenience of monthly dosing.
The commercial launch of the daily oral non-peptide Foundayo challenges the market positioning of injectable therapeutics.